Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia

Deferasirox is an oral iron‐chelating agent having possible antileukemia and immune modulatory effects. Few reports have evaluated deferasirox in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the impact of deferasirox after allo‐HSCT in acute myeloid...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Byung‐Sik, Jeon, Young‐Woo, Hahn, A‐Reum, Lee, Tai‐Hyang, Park, Sung‐Soo, Yoon, Jae‐Ho, Lee, Sung‐Eun, Eom, Ki‐Seong, Kim, Yoo‐Jin, Lee, Seok, Min, Chang‐Ki, Cho, Seok‐Goo, Lee, Jong‐Wook, Min, Woo‐Sung, Kim, Hee‐Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382990/
https://www.ncbi.nlm.nih.gov/pubmed/30677244
http://dx.doi.org/10.1002/cam4.1928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382990/
https://www.ncbi.nlm.nih.gov/pubmed/30677244
http://dx.doi.org/10.1002/cam4.1928

Ejemplares similares